To the Editor:
The hepcidin hormone of 25 amino acid residues (hepcidin-25) 1 is a key regulator of iron homeostasis (1 ) . Hepcidin has been shown to bind in vitro to ␣ 2 -macroglobulin (␣2M) and albumin in human plasma (2 ) . It is not known, however, to what extent hepcidin is bound to proteins in vivo. For purposes of clinical interpretation, it is critical to know whether protein-bound or free hepcidin is being quantified.
To characterize the binding of hepcidin to plasma proteins, we used to gel filtration to fractionate 0.5 mL serum samples from both healthy individuals and patients undergoing hematopoietic stem cell transplantation. We similarly fractionated mixtures of hepcidin and ␣2M or albumin [1 g/L in 10 mmol/L potassium phosphate buffer, pH 7.4, containing 150 mmol/L NaCl (PBS)]. We used a Superdex™ 200 10/300 GL column (GE Healthcare Biosciences) equilibrated with PBS at a flow rate 0.5 mL/min. The column was calibrated with synthetic hepcidin-25 (Peptide Institute), human albumin, and ␣2M. We collected 0.5-mL fractions and measured hepcidin in the fractions by HPLC-tandem mass spectrometry (LC-MS/MS) as previously described (3 ). We observed a single peak, corresponding to free hepcidin, eluting at 21-25 mL. In patient sera containing 36.6 nmol/L (102 g/L) and 50.4 nmol/L (141 g/L) endogenous hepcidin, LC-MS/MS analysis revealed very small hepcidin peaks in fractions containing ␣2M and albumin, respectively (Table 1) , but the hepcidin concentration was below the limit of quantification (3 ). The hepcidin peak area corresponded to 0.7% and 0.9% of the main hepcidin peak, respectively, in the ␣2M fractions and to 0.9% and 1.3% of the main hepcidin peak, respectively, in the albumin fractions. Thus, approximately 98% of hepcidin was free in samples with increased hepcidin. This result contrasts with the findings of Peslova et al., who calculated that only 11% of hepcidin in the circulation was free (2 ) . The molar ratio of ␣2M to hepcidin varied from 0.2:1 to 5:1 in their in vitro study, whereas the mean molar ratio of ␣2M to hepcidin in the serum of healthy individuals is 620:1. The much higher proportion of hepcidin relative to the ␣2M concentration that these investigators used can explain the difference between our results and those of Peslova et al. Hepcidin was not detectable in the ␣2M and albumin fractions of healthy individuals.
Hepcidin and the human internal standard ([ 4%, respectively, of the main peak. The proportion of internal standard eluting at 5.1 min was 2.7% and 3.0%, respectively, of the internal standard eluting at 4.8 min. In the albumin fraction of these samples, 66% and 70%, respectively, of the hepcidin eluted at 5.1 min (see Fig. 1 in the Data Supplement that accompanies the online version of this letter at http://www.clinchem.org/content/ vol58/issue7). Of the internal standard added to the albumin fraction, 7.8% and 3.4%, respectively, eluted at 5.1 min (Table 1) . No hepcidin peak was observed at 5.1 min in the ␣2M or hepcidin fractions.
A possible explanation for the late-eluting hepcidin peak is that hepcidin binds to albumin coeluting with hepcidin during sample extraction (3 ) . To confirm that extracted serum samples contained albumin, we fractionated 10 L of Hepcidin fraction 27 000 106 000 --serum extract by SDS-PAGE, excised the main band corresponding to albumin, digested it with trypsin, and identified the resulting peptides by MALDI-TOF mass spectrometry (4 ) . A Mascot search of the resulting spectra showed that the peptides were derived from albumin.
We calculated the recovery of hepcidin in the gel-filtration experiment from the concentrations in the loaded samples and in the hepcidin-containing fractions eluting at 21-25 mL. Our calculated recoveries were 102% for a patient serum sample, 108% for a hepcidin-supplemented serum sample from a healthy individual, 89% for a hepcidin-supplemented ␣2M solution, and 120% for a hepcidin-supplemented albumin solution. These results suggest that hepcidin is extracted fairly completely and that hepcidin occurs mainly in the free form.
Crockett et al. observed an isomer of bioactive hepcidin (purified by receptor affinity beads from serum and urine) that eluted approximately 0.35 min later than the main peak (5 ). This late-eluting variant corresponded to 0.1% of the hepcidin in serum. They did not characterize this late-eluting hepcidin but speculated that it could have been due to a structural change (5 ). It is not clear whether it is identical to the late-eluting form that we observed.
In conclusion, hepcidin occurs mainly in the free form in circulation, with Ͻ3% being bound to ␣2M and albumin. Our LC-MS/MS method differentiates between free and albumin-bound hepcidin and is specific, in practice, for free hepcidin-25.
